Engineered immune cells show promise in Hard-to-Treat leukemia
NCT ID NCT06481735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new type of CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses donor immune cells that are modified to target cancer cells and last longer in the body. The goal is to see if it is safe and effective, with 30 participants expected to enroll.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
-
Department of Hematology, Chinese PLA General Hospital
RECRUITINGBeijing, China
-
Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College
RECRUITINGChangzhi, China
-
Department of Hematology, Peking Union Medical College Hospital
NOT_YET_RECRUITINGBeijing, China
-
Department of Hematology, Tianjin First Central Hospital
RECRUITINGTianjin, China
-
Immune Cell Therapy Center, Blood Disease Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New transplant recipe aims to tame Graft-Versus-Host disease
- Experimental drug RAD001 tested for tough leukemias and lymphomas
- Engineered immune cells take aim at returning blood cancers
- Selective immune cell removal may tame transplant complications
- New hope for tough blood cancers: LP-118 trial launches
- New safety check for Kids' leukemia drug BESPONSA